文献速递哮喘慢阻肺间质性肺疾病

2004至2023年英国四地区哮喘、慢阻肺和间质性肺疾病发病率与患病率:统一分析

Incidence and prevalence of asthma, chronic obstructive pulmonary disease and interstitial lung disease between 2004 and 2023: harmonised analyses of longitudinal cohorts across England, Wales, South-East Scotland and Northern Ireland.
PubMed 文献 · Thorax · 2025-06-16

该研究采用统一方法分析英格兰、威尔士、苏格兰东南部和北爱尔兰2004至2023年哮喘、慢阻肺和间质性肺疾病的流行病学。结果显示哮喘和慢阻肺发病率下降,而间质性肺疾病发病率上升。2019年各地区患病率存在差异,大流行期间诊断数量显著减少。

要点

  • 2019年与2005年相比,哮喘和慢阻肺发病率下降,间质性肺疾病发病率上升。
  • 2019年哮喘患病率在英格兰、威尔士、苏格兰和北爱尔兰分别为9.7%、15.9%、13.2%和7.0%。
  • 大流行期间哮喘、慢阻肺和间质性肺疾病的观察发病率低于预测值。

核心结论

  • 哮喘、慢阻肺和间质性肺疾病影响四地区超过一千万人,大流行期间大量诊断被遗漏。

研究设计与样本

  • 使用英格兰NHS、CPRD Aurum、威尔士SAIL、苏格兰东南部DataLoch和北爱尔兰Honest Broker Service数据,采用统一病例定义、研究设计和人群进行纵向队列分析。

主要发现

  • 2019年与2005年相比,哮喘发病率比在英格兰为0.89(95%CI 0.88-0.90),威尔士为0.66(0.65-0.68),苏格兰为0.67(0.64-0.71),北爱尔兰为0.84(0.81-0.86)。
  • 2019年与2005年相比,慢阻肺发病率比在英格兰为0.83(0.82-0.85),威尔士为0.67(0.65-0.69)。
  • 2019年与2005年相比,间质性肺疾病发病率比在英格兰为3.27(3.05-3.50),威尔士为1.39(1.27-1.53),苏格兰为1.63(1.36-1.95),北爱尔兰为3.03(2.47-3.72)。
  • 2019年英格兰、威尔士、苏格兰和北爱尔兰的哮喘患病率分别为9.7%、15.9%、13.2%和7.0%;慢阻肺为4.5%、5.1%、4.4%和3.0%;间质性肺疾病为0.4%、0.5%、0.6%和0.3%。
  • 大流行高峰时,哮喘、慢阻肺和间质性肺疾病的预测发病率分别比观察发病率低2.8、3.4和1.8倍。

临床怎么用

  • 临床医生应认识到大流行期间哮喘、慢阻肺和间质性肺疾病诊断可能被遗漏,需加强病例发现和随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We describe the epidemiology of asthma, chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) from 2004 to 2023 in England, Wales, Scotland and Northern Ireland (NI) using a harmonised approach. METHODS: Data from the National Health Service England (NHSE), Clinical Practice Research Datalink Aurum in England, Secure Anonymised Information Linkage Databank in Wales, DataLoch in South-East Scotland and the Honest Broker Service in NI were used. A harmonised approach to COPD, asthma and ILD case definitions, study designs and study populations across the four nations was performed. Age-sex-standardised incidence rates and point prevalence were calculated between 2004 and 2023 depending on data availability. Logistic and negative binomial regression compared incidence and prevalence rates between the start and end of each study period. Linear extrapolation projected incidence rates between 2020 and 2023 to illustrate how observed and projected rates differed. RESULTS: Incidence rates were lower in 2019 versus 2005 for asthma (England: incidence rate ratio 0.89, 95% CI 0.88 to 0.90; Wales: 0.66, 0.65 to 0.68; Scotland: 0.67, 0.64 to 0.71; NI: 0.84, 0.81 to 0.86), COPD (England: 0.83, 0.82 to 0.85; Wales: 0.67, 0.65 to 0.69) and higher for ILD (England: 3.27, 3.05 to 3.50; Wales: 1.39, 1.27 to 1.53; Scotland: 1.63, 1.36 to 1.95; NI: 3.03, 2.47 to 3.72). In NHSE, the incidence of asthma was similar in June 2023 versus November 2019, but lower for COPD and higher for ILD. Prevalence of asthma in 2019 in England, Wales, Scotland and NI was 9.7%, 15.9%, 13.2% and 7.0%, respectively, for COPD 4.5%, 5.1%, 4.4% and 3.0%, and for ILD 0.4%, 0.5%, 0.6% and 0.3%. Projected incidence rates were 2.8, 3.4 and 1.8 times lower for asthma, COPD and ILD compared with observed rates at the height of the pandemic. INTERPRETATION: Asthma, COPD and ILD affect over 10 million people across the four nations, and a substantial number of diagnoses were missed during the pandemic.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Whittaker H, Kramer Fiala Machado A, Hatam S, et al. Incidence and prevalence of asthma, chronic obstructive pulmonary disease and interstitial lung disease between 2004 and 2023: harmonised analyses of longitudinal cohorts across England, Wales, South-East Scotland and Northern Ireland. Thorax. 2025. PMID: 40199588. doi:10.1136/thorax-2024-222699

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。